Novel positron emission tomography/computed tomography of diffuse parenchymal lung disease combining a labeled somatostatin receptor analogue and 2-deoxy-2[ 18F]fluoro-D-glucose

Molecular Imaging

Volumn 11, Issue 2, 2012, Pages 91-98

  Win, Thida ^a,b,c,d,e   Screaton, Nicholas J ^a,b,c,d,e   Porter, Joanna ^a,b,c,d,e   Endozo, Raymondo ^a,b,c,d,e   Wild, Damian ^a,b,c,d,e   Kayani, Irfan ^a,b,c,d,e   Dickson, John ^a,b,c,d,e   Shortman, Robert I ^a,b,c,d,e   Reubi, Jean C ^a,b,c,d,e   Ell, Peter J ^a,b,c,d,e   Groves, Ashley M ^a,b,c,d,e  

^a LISTER HOSPITAL   (United Kingdom)

^b PAPWORTH HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2-DEOXY-2; COMPUTED TOMOGRAPHY; FLUORO D GLUCOSE; GAS TRANSFER; IDIOPATHIC PULMONARY FIBROSIS; IN-VIVO; MEAN AGES; PET TRACER; POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHIES; SOMATOSTATIN RECEPTORS; STANDARDIZED UPTAKE VALUES; TRANSFER FACTOR;

BIOLOGICAL ORGANS; CARBON MONOXIDE; COMPUTERIZED TOMOGRAPHY; GALLIUM; PULMONARY DISEASES;

POSITRON EMISSION TOMOGRAPHY;

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; SOMATOSTATIN RECEPTOR;

AGED; ARTICLE; CLINICAL TRIAL; FEMALE; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; MALE; METABOLISM; METHODOLOGY; SCINTISCANNING; STAINING;

AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; IDIOPATHIC PULMONARY FIBROSIS; LUNG DISEASES, INTERSTITIAL; MALE; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RECEPTORS, SOMATOSTATIN; STAINING AND LABELING;

EID: 84860748977     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2011.00030     Document Type: Article

References (34)

1. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Resp Crit Care Med 1994;150:967-72. (Pubitemid 24318021)
2. Joint Statement of the American Thoracic Society (ATS) the European Respiratory Society (ERS) American Thoracic Society/ European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias, Am J Respir Crit Care Med 2002;165:277-304.
3. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001;345:517-25, doi: 10.1056/NEJMra003200. (Pubitemid 32758505)
4. Dempsey OJ. Clinical review: idiopathic pulmonary fibrosis-past, present and future. Respir Med 2006;100:1871-85, doi: 10.1016/ j.rmed.2006.08.017. (Pubitemid 44490296)
5. Klinsberg RC, Mutsaers SE, Lasky JA. Current clinical trials for the treatment of idiopathic pulmonary fibrosis. Respirology 2010;15: 19-31, doi: 10.1111/j.1440-1843.2009.01672.x.
6. Groves AM, Win T, Screaton NJ, et al. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG-PET/CT. J Nucl Med 2009;50: 538-45, doi: 10.2967/jnumed.108.057901.
7. Umeda Y, Demura Y, Ishizaki T, et al. Dual-time-point 18F-FDG PET imaging for diagnosis of disease type and disease activity in patients with idiopathic interstitial pneumonia. Eur J Nucl Med Mol Imaging 2009;36:1121-30, doi: 10.1007/s00259-009-1069-1.
8. Nusair S, Rubinstein R, Freedman NM, et al. Positron emission tomography in interstitial lung disease. Respirology 2007;12:843-7, doi: 10.1111/j.1440-1843.2007.01143.x. (Pubitemid 350064024)
9. Meissner H, Soo Hoo GW, Khonsary SA, et al. Idiopathic pulmonary fibrosis: evaluation with positron emission tomography. Respiration 2006;73:197-202.
10. Groves AM, Win T, Ben Haim S, Ell PJ. Non FDG PET tracers in clinical oncology. Lancet Oncol 2007;8:822-30, doi: 10.1016/ S1470-2045(07)70274-7. (Pubitemid 47308671)
11. Kayani I, Bomanji JB, Groves A, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga- DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer 2008;112:2447-55, doi: 10.1002/cncr.23469.
12. Jones H, Sriskandan S, Peters A, et al. Dissociation of neutrophil emigration and metabolic activity in lobar pneumonia and bronchiectasis. Eur Respir J 1997;10:795-803. (Pubitemid 27180189)
13. Chen DL, Ferkol TW, Mintun MA, et al. Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography. Am J Respir Crit Care Med 2006;173:1363-9, doi: 10.1164/ rccm.200506-934OC. (Pubitemid 43900711)
14. Hiruma K, Koike T, Nakamura H, et al. Somatostatin receptors on human lymphocytes and leukaemia cells. Immunology 1990;71: 480-5.
15. Varecza Z, Elekes K, László T, et al. Expression of the somatostatin receptor subtype 4 in intact and inflamed pulmonary tissues. J Histochem Cytochem 2009;57:1127-33, doi: 10.1369/jhc.2009.953919.
16. Borie R, Fabre A, Prost F, et al. Activation of somatostatin receptors attenuates pulmonary fibrosis. Thorax 2008;63:251-8, doi: 10.1136/thx.2007. 078006.
17. Lebtahi R, Moreau S, Marchand-Adam S, et al. Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis. J Nucl Med 2006;47:1281-7. (Pubitemid 47544880)
18. Farr RF, Allisy-Roberts PJ. Gamma imaging. In: Farr RF, Allisy- Roberts PJ, editors. Physics for medical imaging. 1st ed. London: Saunders; 1997. p. 118-47.
19. Decristoforo C, Knopp R, von Guggenberg E, et al. A fully automated synthesis for the preparation of 68Ga-labelled peptides. Nucl Med Commun 2007;28:870-5, doi: 10.1097/MNM.0b013e3282f1753d. (Pubitemid 47494113)
20. Groves AM, Kayani I, Dickson JC, et al. Oral contrast medium in PET/CT: should you or shouldn't you? Eur J Nucl Med Mol Imaging 2005;32:1160-6, doi: 10.1007/s00259-005-1833-9. (Pubitemid 41355942)
21. Flaherty KR, Toews GB, Travis WD, et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 2002;19:275-83, doi: 10.1183/09031936.02.00182002. (Pubitemid 34162828)
22. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998;157:1301-15.
23. Müller NL, Staples CA, Miller RR, et al. Disease activity in idiopathic pulmonary fibrosis: CT and pathologic correlation. Radiology 1987;165:731-4. (Pubitemid 18003201)
24. Screaton NJ, Hiorns MP, Lee KS, et al. Serial high resolution CT in non-specific interstitial pneumonia: prognostic value of the initial pattern. Clin Radiol 2005;60:96-104, doi: 10.1016/j.crad.2004.06.029. (Pubitemid 40103906)
25. Shastry M, Kayani I, Wild D. Distribution pattern of 68Ga- DOTATATE in disease-free patients. Nucl Med Commun 2010;31: 1025-32.
26. Ambrosini V, Zompatori M, De Luca F, et al. 68Ga-DOTANOC PET/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: preliminary results. J Nucl Med 2010;51: 1950-5, doi: 10.2967/jnumed.110.079962.
27. Treatment of idiopathic pulmonary fibrosis with long acting octreotide (FIBROSAND). Available at: http://clinicaltrials.gov/ct2/ show/NCT00463983 (accessed December 2010).
28. Krenning EP, Kwekkeboom DJ, Pauwels S, et al. Somatostatin receptor scintigraphy. In: Freeman LM, editor. Nuclear medicine annual. New York: Raven Press; 1995. p. 1-50.
29. Reubi JC, Kvols LK, Waser B, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990;50:5969-77. (Pubitemid 20331408)
30. Korner M, Eltschinger V, Waser B, et al. Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography. Am J Surg Pathol 2005;29: 1642-51, doi: 10.1097/01.pas.0000174013.14569.90.
31. Adams RL, Adams IP, Lindow SW, et al. Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br J Cancer 2005;92:1493-8, doi: 10.1038/sj.bjc.6602503. (Pubitemid 40705017)
32. Ebina M, Shimizukawa M, Shibata N, et al. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004;169:1203-8, doi: 10.1164/ rccm.200308-1111OC. (Pubitemid 38680397)
33. Srirajaskanthan S, Kayani I, Quigley AM, et al. The role of 68Ga- DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DPTA-octreotide scintigraphy. J Nucl Med 2010;51:875-82, doi: 10.2967/jnumed.109.066134.
34. Pettinato C, Sarnelli A, Di Donna M, et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008;35:72-9, doi: 10.1007/s00259-007-0587-y. (Pubitemid 350234154)